Back

Factors associated with futility in transcatheter aortic valve replacement: a single-center analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Predicting outcomes after TAVI Aortic Valve Intervention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Clara Nuevo-Gallardo

University Hospital of Badajoz, Badajoz (Spain)

6 More presentations in this session

Presentation thumbnail
Clinical clustering TAVI patients: multivariate analysis of risk factors, clinical presentation, profiling and outcome association using a two-step cluster analysis
Mr A. Rocha De Almeida (Evora, PT)
Abstract Slides Video
Presentation thumbnail
Periprocedural changes in an AI-based ECG model predict post-TAVR clinical outcomes
Doctor M. Segar (Houston, US)
Abstract Slides Video
Presentation thumbnail
Distinct features of predictive profiles for poor functional improvement and mortality after TAVR. Incremental value of 6-minute walk test
Doctor J. Rychlewski (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Prognostic factors and outcomes in patients under 75 years old receiving transcatheter aortic valve implantation: insights from the LAPLACE registry
Assistant Professor R. Matsuo (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Outcomes of transcatheter aortic valve implantation in young low-risk patients: a comprehensive meta-analysis of efficacy and safety
Mr A. Rocha De Almeida (Evora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting outcomes after TAVI

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
A geriatric assessment score for predicting one-year survival after transcatheter aortic valve implantation: the multicenter GASS-TAVI study
thumbnail
Congress Presentation
Fu-TRI-L score: a futility score in patients with severe tricuspid regurgitation
thumbnail
Congress Presentation
Assessing TAVI: vital clinical impact or therapeutic ineffectiveness?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources